Wednesday, July 23, 2014

Vaccine Development Advancing Due to New Technologies

Vaccine development may significantly improve as technology on the fields of antigens, genomics and immunological monitoring advances. The report published in Nature Immunology stated that a focus on the human immune system will overcome the challenges posed by the animal immune system. The team that wrote this report stated that a leveraging of this technology will provide a better
understanding of specific antigens need for protective immunity.

According to WRAL Tech Wire, North Carolina has emerged as the world leader in vaccine development. It is home to two of the world’s most advanced vaccine manufacturing factories, built by the federal government to be the first responders when diseases are spread. North Carolina has a total of 28 vaccine companies that are employing a total of 13,000 in development or manufacturing

Accelerating HIV vaccine discovery and development may require paradigm shift according to twelve national and international experts in HIV and non-HIV vaccine discovery and development. These experts exchanged information from the perspectives of basic science, regulatory affairs and industry at the Canadian HIV Vaccine Initiative (CHVI) Research and Development Alliance Coordinating Office (ACO) Annual Meeting held in St. John's, Newfoundland on May 1, 2014. "HIV vaccine research and development requires a collaborative, global effort where researchers, funders and industry work together towards a common goal," says ACO Director Greg Hammond according to CNW. "HIV vaccine research and development may further benefit from closer ties to the research and development communities of non-HIV vaccines, where there is much in common and mutual benefits may be expected."

This October at BioProcess International, we'll have a variety of sessions looking at the biopharmaceutical manufacturing and drug discovery of vaccines including the sessions "Biomanufacturing Strategies to Prepare for the Pipeline of the Future" presented by Philippe-Alexandre Gilbert, Ph.D., Head of Upstream Development, Novartis Vaccines & Diagnostics, Inc, "Innovative Characterization Methods to Identify an Optimal Vaccine Drug Product Formulation" presented by Merck Research Labs and more. For more information on these sessions and the rest of the program, download the agenda.  If you'd like to join us, as a reader of this blog, when you register to join us and mention code BPI14BLOG, you'll save 20% off the standard rate.

Share this article with your social network, just click below to share now!

No comments :

Post a Comment